German biotech startup Ethris to raise €15M from Cipla EU to develop mRNA-based therapies
Ethris has forged a new path from genes to therapeutic proteins by employing its non-immunogenic messenger RNA and lipidoid nanoparticle technology platforms to identify, design, and produce novel medicines and vaccines.